In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile

Antimicrob Agents Chemother. 2012 Nov;56(11):5986-9. doi: 10.1128/AAC.00015-12. Epub 2012 Aug 6.

Abstract

The MIC(90) of RBx 14255, a novel ketolide, against Clostridium difficile was 4 μg/ml (MIC range, 0.125 to 8 μg/ml), and this drug was found to be more potent than comparator drugs. An in vitro time-kill kinetics study of RBx 14255 showed time-dependent bacterial killing for C. difficile. Furthermore, in the hamster model of C. difficile infection, RBx 14255 demonstrated greater efficacy than metronidazole and vancomycin, making it a promising candidate for C. difficile treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / chemical synthesis
  • Anti-Bacterial Agents / pharmacology*
  • Clostridioides difficile / drug effects*
  • Clostridioides difficile / growth & development
  • Cricetinae
  • Drug Resistance, Bacterial / drug effects
  • Enterocolitis, Pseudomembranous / drug therapy*
  • Enterocolitis, Pseudomembranous / microbiology
  • Enterocolitis, Pseudomembranous / mortality
  • Humans
  • Ketolides / chemical synthesis
  • Ketolides / pharmacology*
  • Metronidazole / pharmacology
  • Microbial Sensitivity Tests
  • Survival Rate
  • Vancomycin / pharmacology

Substances

  • Anti-Bacterial Agents
  • Ketolides
  • Rbx 14255
  • Metronidazole
  • Vancomycin